Novartis Not Nervous About SGLT2 Threat To Entresto
Cardiovascular Blockbuster Closing In On $4-$5bn Sales Guidance
The company's pharma chief Marie-France Tschudin does not expect Entresto's "unique position" in heart failure to be threatened by SGLT2 inhibitors such as Jardiance and Farxiga, saying those drugs are add-ons that will be used predominantly in diabetes patients.
